BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 target...BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 targeting drug independently developed in China,exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab,which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy.In this case,the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension,poor appetite,and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery,followed by tegafur monotherapy for six months.The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma.He received 17 cycles of a combination of inetetamab,an innovative domestically developed anti-HER2 monoclonal antibody,and tegafur chemotherapy as the second-line treatment(inetetamab 200 mg on day 1,every 3 wk combined with tegafur twice daily on days 1–14,every 3 wk).Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months.He tolerated the treatment well without exhibiting any grade 3-4 adverse events.CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.展开更多
目的:比较使用不同模式Er:YAG激光以及传统车针去龋后牙本质与复合树脂的粘接强度。方法:选用人类离体磨牙模拟龋坏,分别采用Er:YAG激光中短脉冲(medium short pulse,MSP)模式、Er:YAG激光超短脉冲(super short pulse,SSP)模式和传统车...目的:比较使用不同模式Er:YAG激光以及传统车针去龋后牙本质与复合树脂的粘接强度。方法:选用人类离体磨牙模拟龋坏,分别采用Er:YAG激光中短脉冲(medium short pulse,MSP)模式、Er:YAG激光超短脉冲(super short pulse,SSP)模式和传统车针去除模拟的龋坏后,采用自酸蚀粘接剂将牙体标本与复合树脂粘接制成试件。使用万能试验机对试件进行拉伸试验,测得断裂负荷和粘接强度,并采用单因素方差分析和Tukey多重比较进行统计学分析。采用扫描电子显微镜观察3种不同去龋方式处理后的牙本质表面形态,以及涂布自酸蚀粘接剂并固化后试件的横截面形态。结果:使用Er:YAG激光MSP模式处理后牙本质与复合树脂的粘接强度最高,SSP模式处理后次之,传统车针处理后最低,但差异无统计学意义(P>0.05)。扫描电子显微镜图像显示,Er:YAG激光MSP模式处理后的牙本质表面较平坦,牙本质小管内几乎没有残屑;Er:YAG激光SSP模式处理后的牙本质表面呈现鳞片状,牙本质小管内可见少量碎屑;而传统车针处理后牙本质小管大部分处于被表面牙本质部分甚至完全遮盖的状态,牙本质小管内充满残屑。结论:使用Er:YAG激光去龋相比传统车针去龋可以获得较好的牙本质粘接强度,且对牙本质小管的处理深度和洁净度明显优于传统车针去龋,其中MSP模式更佳。展开更多
BACKGROUND Programmed death receptor-1(PD-1)inhibitors have been approved as secondline treatment regimen in hepatocellular carcinoma(HCC),but it is still worth studying whether patients can benefit from PD-1 inhibito...BACKGROUND Programmed death receptor-1(PD-1)inhibitors have been approved as secondline treatment regimen in hepatocellular carcinoma(HCC),but it is still worth studying whether patients can benefit from PD-1 inhibitors as first-line drugs combined with targeted drugs and locoregional therapy.AIM To estimate the clinical outcome of transarterial chemoembolization(TACE)and lenvatinib plus PD-1 inhibitors for patients with unresectable HCC(uHCC).METHODS We carried out retrospective research of 65 patients with uHCC who were treated at Peking Union Medical College Hospital from September 2017 to February 2022.45 patients received the PD-1 inhibitors,lenvatinib,TACE(PD-1-Lenv-T)therapy,and 20 received the lenvatinib,TACE(Lenv-T)therapy.In terms of the dose of lenvatinib,8 mg was given orally for patients weighing less than 60 kg and 12 mg for those weighing more than 60 kg.Of the patients in the PD-1 inhibitor combination group,15 received Toripalimab,14 received Toripalimab,14 received Camrelizumab,4 received Pembrolizumab,9 received Sintilimab,and 2 received Nivolumab,1 with Tislelizumab.According to the investigators’assessment,TACE was performed every 4-6 wk when the patient had good hepatic function(Child-Pugh class A or B)until disease progression occurred.We evaluated the efficacy by the modified Response Evaluation Criteria in Solid Tumors(mRECIST criteria).We accessd the safety by the National Cancer Institute Common Terminology Criteria for Adverse Events,v 5.0.The key adverse events(AEs)after the initiation of combination therapy were observed.RESULTS Patients with uHCC who received PD-1-Lenv-T therapy(n=45)had a clearly longer overall survival than those who underwent Lenv-T therapy(n=20,26.8 vs 14.0 mo;P=0.027).The median progression-free survival time between the two treatment regimens was also measured{11.7 mo[95%confidence interval(CI):7.7-15.7]in the PD-1-Lenv-T group vs 8.5 mo(95%CI:3.0-13.9)in the Lenv-T group(P=0.028)}.The objective response rates of the PD-1-Lenv-T group and Lenv-T group were 44.4%and 20%(P=0.059)according to the mRECIST criteria,meanwhile the disease control rates were 93.3%and 64.0%(P=0.003),respectively.The type and frequency of AEs showed little distinction between patients received the two treatment regimens.CONCLUSION Our results suggest that the early combination of PD-1 inhibitors has manageable toxicity and hopeful efficacy in patients with uHCC.展开更多
转镜调Q无插入损耗,是获得窄脉冲、高峰值功率输出激光的直接方式。纳秒脉冲需要使用高速转镜调Q,并精准控制电机转速与氙灯放电延时,以使激光介质上能级粒子数反转最大,获得最大激光能量输出。本文设计了以Arduino mega 2560单片机为...转镜调Q无插入损耗,是获得窄脉冲、高峰值功率输出激光的直接方式。纳秒脉冲需要使用高速转镜调Q,并精准控制电机转速与氙灯放电延时,以使激光介质上能级粒子数反转最大,获得最大激光能量输出。本文设计了以Arduino mega 2560单片机为核心的高速转镜调Q控制系统,通过精确单片机解析串口屏指令控制激光电源的充放电和高速电机启停,同时通过对转镜脉冲信号整合降频控制氙灯放电时刻,实现对延迟时间的精准控制,实现了灯泵Er,Cr:YSGG激光纳秒窄脉冲调Q输出。在5 Hz重复频率下,转镜转速为650 r/s时,获得的最高单脉冲激光能量为45.7 mJ、脉冲宽度为86.2 ns,相应的峰值功率为530.2 kW。展开更多
基金Supported by the Science and Technology Innovation Development Project of Tai’an,No.2021NS160the Medical and Health Science and Technology Development Plan of Shandong Province,No.202102010647。
文摘BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 targeting drug independently developed in China,exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab,which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy.In this case,the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension,poor appetite,and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery,followed by tegafur monotherapy for six months.The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma.He received 17 cycles of a combination of inetetamab,an innovative domestically developed anti-HER2 monoclonal antibody,and tegafur chemotherapy as the second-line treatment(inetetamab 200 mg on day 1,every 3 wk combined with tegafur twice daily on days 1–14,every 3 wk).Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months.He tolerated the treatment well without exhibiting any grade 3-4 adverse events.CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.
文摘目的:比较使用不同模式Er:YAG激光以及传统车针去龋后牙本质与复合树脂的粘接强度。方法:选用人类离体磨牙模拟龋坏,分别采用Er:YAG激光中短脉冲(medium short pulse,MSP)模式、Er:YAG激光超短脉冲(super short pulse,SSP)模式和传统车针去除模拟的龋坏后,采用自酸蚀粘接剂将牙体标本与复合树脂粘接制成试件。使用万能试验机对试件进行拉伸试验,测得断裂负荷和粘接强度,并采用单因素方差分析和Tukey多重比较进行统计学分析。采用扫描电子显微镜观察3种不同去龋方式处理后的牙本质表面形态,以及涂布自酸蚀粘接剂并固化后试件的横截面形态。结果:使用Er:YAG激光MSP模式处理后牙本质与复合树脂的粘接强度最高,SSP模式处理后次之,传统车针处理后最低,但差异无统计学意义(P>0.05)。扫描电子显微镜图像显示,Er:YAG激光MSP模式处理后的牙本质表面较平坦,牙本质小管内几乎没有残屑;Er:YAG激光SSP模式处理后的牙本质表面呈现鳞片状,牙本质小管内可见少量碎屑;而传统车针处理后牙本质小管大部分处于被表面牙本质部分甚至完全遮盖的状态,牙本质小管内充满残屑。结论:使用Er:YAG激光去龋相比传统车针去龋可以获得较好的牙本质粘接强度,且对牙本质小管的处理深度和洁净度明显优于传统车针去龋,其中MSP模式更佳。
基金Supported by Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences,No.2021-I2M-1-061 and 2021-I2M-1-003Chinese Society of Clinical Oncology-Hengrui Cancer Research Fund,No.Y-HR2019-0239+1 种基金Chinese Society of Clinical Oncology-MSD Cancer Research Fund,No.Y-MSDZD2021-0213National Ten-thousand Talent Program.
文摘BACKGROUND Programmed death receptor-1(PD-1)inhibitors have been approved as secondline treatment regimen in hepatocellular carcinoma(HCC),but it is still worth studying whether patients can benefit from PD-1 inhibitors as first-line drugs combined with targeted drugs and locoregional therapy.AIM To estimate the clinical outcome of transarterial chemoembolization(TACE)and lenvatinib plus PD-1 inhibitors for patients with unresectable HCC(uHCC).METHODS We carried out retrospective research of 65 patients with uHCC who were treated at Peking Union Medical College Hospital from September 2017 to February 2022.45 patients received the PD-1 inhibitors,lenvatinib,TACE(PD-1-Lenv-T)therapy,and 20 received the lenvatinib,TACE(Lenv-T)therapy.In terms of the dose of lenvatinib,8 mg was given orally for patients weighing less than 60 kg and 12 mg for those weighing more than 60 kg.Of the patients in the PD-1 inhibitor combination group,15 received Toripalimab,14 received Toripalimab,14 received Camrelizumab,4 received Pembrolizumab,9 received Sintilimab,and 2 received Nivolumab,1 with Tislelizumab.According to the investigators’assessment,TACE was performed every 4-6 wk when the patient had good hepatic function(Child-Pugh class A or B)until disease progression occurred.We evaluated the efficacy by the modified Response Evaluation Criteria in Solid Tumors(mRECIST criteria).We accessd the safety by the National Cancer Institute Common Terminology Criteria for Adverse Events,v 5.0.The key adverse events(AEs)after the initiation of combination therapy were observed.RESULTS Patients with uHCC who received PD-1-Lenv-T therapy(n=45)had a clearly longer overall survival than those who underwent Lenv-T therapy(n=20,26.8 vs 14.0 mo;P=0.027).The median progression-free survival time between the two treatment regimens was also measured{11.7 mo[95%confidence interval(CI):7.7-15.7]in the PD-1-Lenv-T group vs 8.5 mo(95%CI:3.0-13.9)in the Lenv-T group(P=0.028)}.The objective response rates of the PD-1-Lenv-T group and Lenv-T group were 44.4%and 20%(P=0.059)according to the mRECIST criteria,meanwhile the disease control rates were 93.3%and 64.0%(P=0.003),respectively.The type and frequency of AEs showed little distinction between patients received the two treatment regimens.CONCLUSION Our results suggest that the early combination of PD-1 inhibitors has manageable toxicity and hopeful efficacy in patients with uHCC.
